Last $43.44 USD
Change Today +0.09 / 0.21%
Volume 4.2M
GSK On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 4:15 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSK) Key Developments

GlaxoSmithKline Announces Earnings Results for the First Half of 2014

GlaxoSmithKline announced earnings results for the first half of 2014. The company's sales in the first half of 2014 were worse than expected after revealing a turnover of 5.6 billion, down 4% from the same time last year, and core earnings down 12%.

GlaxoSmithKline PLC to Cut Hundreds of US Jobs

GlaxoSmithKline PLC's 17,000 U.S.-based employees will lose their jobs by the end of next year under the pharmaceutical industry's latest restructuring. The company announced it will eliminate about 900 jobs in marketing and research in Research Triangle Park, North Carolina, though some cuts will be made through a hiring freeze and not filling vacant positions. Some positions will be shifted to the company's U.S. headquarters in Philadelphia.

GlaxoSmithKline Drops Plans To Sell Older Drugs Business

GlaxoSmithKline plc (LSE:GSK) said that it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. GlaxoSmithKline said, "The company has evaluated all bids received and has concluded, consistent with its key criteria of maximising shareholder value, not to pursue divestment of these products." A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. The sources told Reuters that bidders, who had been hoping to clinch a deal before the end of 2014, included Apollo Global Management, LLC, H. Lundbeck A/S (CPSE:LUN), and KKR & Co. L.P. (NYSE:KKR), which teamed up with Norgine Pharmaceuticals Limited.

GlaxoSmithKline to Invest USD 50.6 Million in its Business in Brazil

GlaxoSmithKline has announced investment of BRL 130 million (USD 50.6 million) in its main facility in Brazil that is located in Rio de Janeiro. The investment will go towards the expansion of the facility and the acquisition of new equipment, with the aim of strengthening the production capacity of the Rio de Janeiro facility.

GlaxoSmithKline plc Returns Rights to Lupus Candidate DV1179 to Dynavax Technologies

Dynavax Technologies has announced that following the expiry of a research and development (R&D) and licence agreement with GlaxoSmithKline it has regained all rights to the systemic lupus erythematosus (SLE) candidate DV1179. DV1179 is a first-in-class investigational toll-like receptor 7 and 9 (TLR7/9) inhibitor that failed to meet the pharmacodynamic endpoints as measured by a reduction in interferon alpha-regulated genes in a Phase Ib/IIa study in patients with SLE. Consequently, GSK declined to exercise its option to licence the candidate.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $43.44 USD +0.09

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $167.27 USD +1.79
AbbVie Inc $66.97 USD -0.74
Biogen Idec Inc $352.29 USD -8.38
Celgene Corp $113.50 USD -3.68
Novo Nordisk A/S kr267.20 DKK +1.20
View Industry Companies
 

Industry Analysis

GSK

Industry Average

Valuation GSK Industry Range
Price/Earnings 15.7x
Price/Sales 2.7x
Price/Book 12.8x
Price/Cash Flow 15.6x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.